Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daflon 1000 mg versus Daflon 500 mg in symptomatic chronic venous disease
2012-003559-13Phase 3Completed
- Sponsor
- Servier
- Start
- Apr 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of diosmin in chronic venous disease (CVD) and venous stasis (2 arms), sponsored by Servier. Primary endpoint: Lower limb discomfort improvement. Started Apr 2013; status: completed.
02
Drugs
diosmin
03
Conditions
chronic venous disease (CVD)venous stasis
Beyond the preview
Go deeper on 2012-003559-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003559-13.